Glaucoma Clinical Trials in New York, NY

View the best 10 glaucoma medical studies in New York, New York. Access promising new therapies by applying to a New York-based Glaucoma clinical trial.

Trials in New York, New York

Here are the top 9 medical studies for glaucoma in New York, New York

T4090 +1 More

Procedure

Recruiting1 awardPhase 2

This trial aims to compare the effectiveness and safety of two different concentrations of T4090 eye drops (0.2% and 0.3%) with Rhopressa® eye drops in reducing

Streamline Surgical System +1 More

Device

Recruiting1 award1 criteria

This trial compared the Streamline Surgical System to a competitor for use in surgeries.

NCX 470 0.1% +1 More

Prostaglandin Analog

Recruiting2 awardsPhase 3

This trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.

Placebo +1 More

Recruiting0 awardsPhase 2 & 3

This trial studies if N&P can help keep eyes healthy when treating glaucoma with standard meds.

Low Energy SLT +1 More

Laser Therapy

Recruiting1 award

This trial is testing if a lower-energy version of a common glaucoma treatment is as effective as the standard treatment, and if repeating the lower-energy treatment yearly is better than waiting for the treatment to wear off.

ELIOS Procedure

Excimer Laser

Recruiting1 award

This trial evaluates the safety and effectiveness of the ELIOS System, a procedure to lower eye pressure, in adults with mild to moderate primary open-angle glaucoma who are undergoing cataract surgery.

Repetitive, Transorbital Alternating Current Stimulation (rtACS)

Electrical Stimulation

Recruiting0 awards

This trial is testing if using a home device that sends small electrical pulses to the eyes can help treat open-angle glaucoma. This condition causes eye nerves to die off quickly, and the study aims to see if this new method is safe and effective.

System-Level Intervention

Behavioural Intervention

Recruiting0 awards2 criteria

This trial aims to provide eye health screenings in Upper Manhattan communities to address disparities in eye and vision health. The study will recruit adults aged 40 and older from diverse backgrounds and conduct ocular tests during

Arm 1 +2 More

Stem Cell Therapy

Recruiting1 award8 criteria

This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.

Popular Filters

Trials With No Placebo

Procedure

T4090 vs Rhopressa for Glaucoma

Recruiting1 awardPhase 2

Poughkeepsie, New York

This trial aims to compare the effectiveness and safety of two different concentrations of T4090 eye drops (0.2% and 0.3%) with Rhopressa® eye drops in reducing

Device

Streamline Surgical System vs iStent for Open-Angle Glaucoma

Recruiting1 award1 criteria

Dover, New Jersey

This trial compared the Streamline Surgical System to a competitor for use in surgeries.

Implant

MINIject™ Implant for Glaucoma

Recruiting1 award

New York, New York

This trial is testing a small device called the MINIject™ implant, which is designed to help lower eye pressure in people with primary open-angle glaucoma. The device works by making it easier for fluid to drain from the eye, reducing pressure and potentially preventing vision loss.

Laser Therapy

Selective Laser Trabeculoplasty for Glaucoma

Recruiting1 award

Bronx, New York

This trial is testing if a lower-energy version of a common glaucoma treatment is as effective as the standard treatment, and if repeating the lower-energy treatment yearly is better than waiting for the treatment to wear off.

Excimer Laser

Excimer Laser Trabeculostomy for Glaucoma

Recruiting1 award

South Orange, New Jersey

This trial evaluates the safety and effectiveness of the ELIOS System, a procedure to lower eye pressure, in adults with mild to moderate primary open-angle glaucoma who are undergoing cataract surgery.

Prostaglandin Analog

NCX 470 for Glaucoma

Recruiting2 awardsPhase 3

Bronx, New York

This trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.